10/06/2021 (Agence Europe) – On Thursday 10 June, the European Parliament opposed a draft implementing regulation by the European Commission (EU) 2021/621 to establish a maximum residue level (MRL) for imidacloprid for aquatic use (see EUROPE 12736/5). Imidacloprid is a pharmacologically active substance. The objection resolution was adopted by 441 votes (232 against and 18 abstentions). The European Medicines Agency has recommended setting the MRL at 0.6mg/kg (600 µg/kg) for fin-fish. The European Parliament argues that there is mounting evidence on the devastating effects of using imidacloprid on biodiversity, particularly in rivers and streams. It calls on the European Commission to repeal its implementing regulation and to submit a new proposal that includes imidacloprid on the list of pharmacologically active substances for which no maximum limit can be set for aquatic use. (AN)